Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria

Joint Authors

Satirapoj, Bancha
Supasyndh, Ouppatham
Yongwatana, Kachonsak

Source

Journal of Diabetes Research

Issue

Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-6, 6 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2020-08-11

Country of Publication

Egypt

No. of Pages

6

Main Subjects

Diseases
Medicine

Abstract EN

Background.

Glycosaminoglycan plays an important role in the maintenance of glomerular charge selectivity of diabetic nephropathy.

Sulodexide, a mixture of naturally occurring glycosaminoglycan polysaccharide components, has shown a nephroprotective effect in an experimental model of diabetic nephropathy.

Although sulodexide reduced albuminuria in patients with type 1 and type 2 diabetes, long-term effects in patients with type 2 diabetes with significant proteinuria have not been established.

Objectives.

The study was aimed at investigating the effects of sulodexide on proteinuria and renal function in patients with type 2 diabetes and nephropathy.

Methods.

Fifty-two patients with proteinuria between 500 and 3000 mg/day received sulodexide 200 mg/day for 12 months, while 56 matched patients with type 2 diabetes constituted the control group.

All patients received standard metabolic and blood pressure controls.

Primary outcome was evaluated as percentage of reduced proteinuria compared with the control group.

Renal function was assessed using estimated glomerular filtration rate (GFR).

Results.

Proteinuria significantly increased in the control group [0.9 (IQR 0.3 to 1.78) to 1.16 (IQR 0.44 to 2.23) g/gCr, P=0.001], whereas it remained stable in the sulodexide group [0.66 (IQR 0.23 to 0.67) to 0.67 (IQR 0.17 to 1.51) g/gCr, P=0.108].

At 12 months, proteinuria was higher by 19.4% (IQR 10.3 to 37.6) in the control group while proteinuria was lower by -17.7% (IQR -53.1 to 3.2) in the sulodexide group with a significant difference between groups (P=0.001).

Renal function was noted as a change of estimated GFR, and serum creatinine decreased significantly during the study in both groups but did not significantly differ between groups.

No significant changes in the blood pressure, fasting plasma glucose, and hemoglobin A1C were reported.

Conclusion.

In addition to standard treatment, sulodexide is efficient in maintaining proteinuria in patients with type 2 diabetes with nonnephrotic range proteinuria, but it did not provide an additional benefit concerning renal disease progression.

American Psychological Association (APA)

Yongwatana, Kachonsak& Supasyndh, Ouppatham& Satirapoj, Bancha. 2020. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria. Journal of Diabetes Research،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1182997

Modern Language Association (MLA)

Yongwatana, Kachonsak…[et al.]. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria. Journal of Diabetes Research No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1182997

American Medical Association (AMA)

Yongwatana, Kachonsak& Supasyndh, Ouppatham& Satirapoj, Bancha. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria. Journal of Diabetes Research. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1182997

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1182997